// App-Quantinova.ai

: A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis

Researchers

Presenter

  • Victoria P. Werth

Principal Investigators

  • Emily Hejazi

  • Sandra M. Pena

  • Jessica S. Haber

  • Joyce Okawa

  • Rui Feng

  • Kirubel Gabre

  • Josef Concha

  • Caitlin Cornwall

  • Nancy Dgetluck

  • Scott Constantine

  • Barbara White

Medical Centers

  • N/A

Locations

  • N/A

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Ajulemic acid

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved